Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing demand for dry powder inhalers (DPI) products (Impact Weightage: 30%)
4.2.2 Compatibility with active ingredients and other excipients (Impact Weightage: 15%)
4.2.3 Approval from government bodies (Impact Weightage: 25%)
4.2.4 Drug formulation coupled with nanotechnology will boost the growth of pharmaceutical grade lactose market (Impact Weightage: 30%)
4.3 Restrains
4.3.1 Lactose-induced problems (Impact Weightage: 40%)
4.3.2 Stringent government regulations (Impact Weightage: 30%)\
4.3.3 Lack compatibility with amine based drugs (Impact Weightage: 30%)
4.4 Opportunity
4.5 Mega Trends
4.5.1 Using lactose as excipient in nanotechnology-based drug formulations
4.6 Macroeconomic Indicators
4.7 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porters Five Forces Model
5.2.1 Bargaining power of suppliers (Medium to High)
5.2.2 Bargaining Power of Buyers (low to medium)
5.2.3 Threat of New Entrants (low to medium)
5.2.4 Threat of Substitutes (High)
5.2.5 Intensity of Rivalry (Medium)
5.3 Demand & Supply: Gap Analysis
5.3.1 Pricing Analysis
5.3.2 Investment Opportunity Analysis
6 Pharmaceutical Grade Lactose Market, by Type
6.1 Introduction
6.2 Crystalline Monohydrate Lactose
6.3 Inhalation Lactose
6.4 Granulated Lactose
6.5 Spray Dried Lactose
7 Global Pharmaceutical Grade Lactose Market, by Application
7.1 Introduction
7.2 Tablets Manufacturing
7.3 Capsule Manufacturing
8 Global Pharmaceutical Grade Lactose Market, by Region
8.1 Introduction
8.2 Europe
8.2.1 Western Europe
8.2.1.1 Germany
8.2.1.2 France
8.2.1.3 UK
8.2.1.4 Italy
8.2.1.5 Spain
8.2.1.6 Rest of Western Europe
8.2.2 Eastern Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Republic of Korea
8.3.5 Australia
8.3.6 Rest of Asia Pacific


8.4 Americas
8.4.1 North America
8.4.1.1 U.S.
8.4.1.2 Canada
8.4.2 South America
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
9 Company Landscape
9.1 Company Share Analysis
9.2 Competitive Landscape
10 Company Profiles
10.1 BASF SE
10.1.1 Company Overview
10.1.2 Financials
10.1.3 Products
10.1.4 Strategy
10.1.5 Key Developments
10.2 Merck KGaA
10.2.1 Company Overview
10.2.2 Financials
10.2.3 Products
10.2.4 Strategy
10.2.5 Key Developments
10.3 Kerry Inc.
10.3.1 Company Overview
10.3.2 Financials
10.3.3 Products
10.3.4 Strategy
10.3.5 Key Developments
10.4 DFE Pharma
10.4.1 Company Overview
10.4.2 Financials
10.4.3 Products
10.4.4 Strategy
10.4.5 Key Developments
10.5 Meggle
10.5.1 Company Overview
10.5.2 Financials
10.5.3 Products
10.5.4 Strategy
10.5.5 Key Developments
10.6 Armor Pharma
10.6.1 Company Overview
10.6.2 Financials
10.6.3 Products
10.6.4 Strategy
10.6.5 Key Developments
10.7 ALPAVIT
10.7.1 Company Overview
10.7.2 Financials
10.7.3 Products
10.7.4 Strategy
10.7.5 Key Developments
11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO's view point
11.2 Key Companies to Watch
12 Appendix
12.1 Discussion Blue Print